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A B S T R A C T
Background
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide, yet CVD risk factor control and secondary
prevention rates remain low. A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a
single pill, or polypill, has been proposed as one strategy to reduce the global burden of CVD by up to 80% given its potential for
better adherence and lower costs.
Objectives
To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood
pressure and lipid CVD risk factors for both primary and secondary prevention of CVD. We also aimed to determine discontinuation
rates, adverse events, health-related quality of life, and costs of fixed-dose combination therapy.
Search methods
We searched theCochrane Central Register of Controlled Trials (CENTRAL) inThe Cochrane Library (2013, Issue 6),MEDLINEOvid
(1946 to week 2 July 2013), EMBASE Ovid (1980 toWeek 28 2013), ISI Web of Science (1970 to 19 July 2013), and the Database of
Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTA), and Health Economics Evaluations Database
(HEED) (2011, Issue 4) in The Cochrane Library. We used no language restrictions.
Selection criteria
We included randomised controlled trials of a fixed-dose combination therapy including at least one blood pressure lowering and one
lipid lowering component versus usual care, placebo, or a single drug active component for any treatment duration in adults≥ 18 years
old with no restrictions on presence or absence of pre-existing cardiovascular disease.
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Data collection and analysis
Three review authors independently selected studies for inclusion and extracted the data. We evaluated risk of bias using the Cochrane
risk of bias assessment tool. We sought to include outcome data on all-cause mortality, fatal and non-fatal CVD events, adverse events,
changes in systolic and diastolic blood pressure, total and low density lipoprotein (LDL) cholesterol concentrations, discontinuation
rates, quality of life, and costs. We calculated risk ratios (RR) for dichotomous data and weightedmean differences (MD) for continuous
data with 95% confidence intervals (CI) using fixed-effect models when heterogeneity was low (I2 < 50%) and random-effects models
when heterogeneity was high (I2 > 50%).
Main results
We found nine randomised controlled trials with a total of 7047 participants. Seven of the nine trials evaluated the effects of fixed-dose
combination therapy on primary CVD prevention, and the trial length ranged from six weeks to 15 months. We found a moderate
to high risk of bias in the domains of selection, performance, detection, attrition, and other types of bias in five of the nine trials.
Compared with the comparator groups, the effects of the fixed-dose combination treatment on mortality (1.2% versus 1.0%, RR
1.26, 95% CI 0.67 to 2.38, N = 3465) and cardiovascular events (4.0% versus 2.9%, RR 1.38, 95% CI 0.91 to 2.10, N = 2479)
were uncertain (low quality evidence). The low event rates for these outcomes, limited availability of data as only two out of nine
trials reported on these outcomes, and a high risk of bias in at least one domain suggest that these results should not be viewed with
confidence. Adverse events were common in both the intervention (30%) and comparator (24%) groups, with participants randomised
to fixed-dose combination therapy being 20% (95% CI 9% to 30%) more likely to report an adverse event. Notably, no serious adverse
events were reported. Compared with placebo, the rate of discontinuation among participants randomised to fixed-dose combination
was higher (14% versus 11%, RR 1.26 95% CI 1.02 to 1.55). The weighted mean differences in systolic and diastolic blood pressure
between the intervention and control arms were -7.05 mmHg (95% CI -10.18 to -3.87) and -3.65 mmHg (95% CI -5.44 to -1.85),
respectively. The weighted mean differences (95% CI) in total and LDL cholesterol between the intervention and control arms were -
0.75 mmol/L (95% CI -1.05 to -0.46) and -0.81 mmol/L (95% CI -1.09 to -0.53), respectively. There was a high degree of statistical
heterogeneity in comparisons of blood pressure and lipids (I2 ≥ 70% for all) that could not be explained, so these results should be
viewed with caution. Fixed-dose combination therapy improved adherence to a multi-drug strategy by 33% (26% to 41%) compared
with usual care, but this comparison was reported in only one study. The effects of fixed-dose combination therapy on quality of life
are uncertain, though these results were reported in only one trial. No trials reported costs.
Authors’ conclusions
Compared with placebo, single drug active component, or usual care, the effects of fixed-dose combination therapy on all-cause
mortality or CVD events are uncertain; only few trials report these outcomes and the included trials were primarily designed to observe
changes in CVD risk factor levels rather than clinical events. Reductions in blood pressure and lipid parameters are generally lower
than those previously projected, though substantial heterogeneity of results exists. Fixed-dose combination therapy is associated with
modest increases in adverse events compared with placebo, single drug active component, or usual care but may be associated with
improved adherence to a multidrug regimen. Ongoing trials of fixed-dose combination therapy will likely inform key outcomes.
P L A I N L A N G U A G E S U M M A R Y
Fixed-dose combination therapy for the prevention of cardiovascular disease
Cardiovascular diseases (CVD), including heart attacks and strokes, are the leading cause of death and disability worldwide.Drug therapy
with blood pressure and cholesterol loweringmedications, particularly statins, have been proven to reduce the likelihood that individuals
will experience a fatal or non-fatal cardiovascular event. Aspirin has also been proven to prevent heart attacks, certain types of strokes, and
death in people with prior cardiovascular disease. The concept of fixed-dose combination therapy is to combine mulitple medications
in a single pill as this has been shown to improve adherence in patients with high blood pressure and human immunodeficiency virus
(HIV). There have been recent randomised controlled clinical trials to evaluate the effect of fixed-dose combination therapy for CVD
prevention. The aim of this systematic review was to determine the effects of fixed-dose combination therapy on all-cause mortality, fatal
and non-fatal CVD events, adverse events, blood pressure, lipids, discontinuation rates, quality of life, and costs for CVD prevention.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE until 2013. We found
nine randomised controlled trials of two-drug through to five-drug fixed-dose combination therapy with placebo, single drug active
component, or usual care in 7047 patients, dating from 2009 to 2013. Trials were generally short-term, ranging from six weeks to 15
months, and included middle-age adults with and without prior CVD.
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Compared with placebo, single drug active component, or usual care, the effects of fixed-dose combination therapy on all-cause
mortality or CVD events were uncertain. However, the event rates for these outcomes were relatively uncommon, only two out of nine
trials reported these outcomes, these trials were primarily designed to observed changes in CVD risk factor levels rather than clinical
events, and the trials had a high risk of bias in at least one domain, suggesting that these results should not viewed with confidence.
Of 1000 people treated with fixed-dose combination therapy during the study period, 297 (range 264 to 315) would experience a
side effect compared with 242 people treated with placebo. Fixed-dose combination therapy was associated with lower systolic blood
pressure (-7.05 mmHg, range -10.18 to -3.87) and total cholesterol (-0.75 mmol/L, range -1.05 to -0.46). However, there was a high
degree of statistical heterogeneity in these comparisons so these results should be viewed with caution. Of 1000 patients treated with
fixed-dose combination therapy during the study period, 140 (range 122 to 186) would discontinue the therapy compared with 115
patients treated with placebo. The effects on quality of life were uncertain, and no cost data were reported. Ongoing trials of fixed-dose
combination therapy will likely inform these important endpoints.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fixed-dose combination therapy for the prevention of cardiovascular disease (CVD)
Patient or population: Adults older than 18 years, with no restriction regarding presence of CVD; participants generally had elevated risk of CVD (as estimated by the presence of at least one
abnormal cardiovascular risk factor) without prevalent CVD (two studies included >10% of participants with prior CVD)
Settings: Outpatient
Intervention: Fixed-dose combination therapy of varying drug combinations ranging from two to five drugs
Comparison: Usual care, placebo, or single drug therapy from alternate drug class
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard practice or
placebo
Fixed-dose combination
therapy
All-cause mortality Total RR = 1.26
[0.67, 2.38]
3465
(2 studies)
⊕⊕©©
low
Downgraded due to study
limitations (risk of bias)
in 1 of 2 included studies
and imprecision of effect
10 per 1000 12 per 1000
(7 to 24)
CVD event Total RR = 1.38 [0.91, 2.10] 2479
(2 studies)
⊕⊕©©
low
Downgraded due to study
limitations (risk of bias)
in 1 of 2 included studies
and imprecision of effect
29 per 1000 40 per 1000
(26 to 61)
Any adverse event
6 weeks to 15 months
Total RR = 1.19
[1.09, 1.30]
4864
(7 studies)
⊕⊕©©
low
Downgraded due to study
limitations (risk of bias)
and difficulty in assessing
indirectness of evidence
242 per 1000 297 per 1000
(264 to 315)
Systolic blood pressure
mmHg
The mean change in
systolic blood pressure
ranged across control
groups from -17.9 mmHg
to -2 mmHg
The mean change in sys-
tolic blood pressure in the
intervention groups was
on average a -7.05mmHg
(95% CI -10.18 to -3.87)
5787
(9 studies)
⊕⊕⊕©
moderate
Downgraded due to study
limitations (risk of bias)
and unexplained hetero-
geneity
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greater reduction com-
pared with control
Diastolic blood pressure
mmHg
The mean change in di-
astolic blood pressure
ranged across control
groups from -9.8 mmHg
to -0.5 mmHg
The mean change in di-
astolic blood pressure in
the intervention groups
was on average a -3.65
mmHg (95% CI -5.44 to
-1.85) greater reduction
compared with control
5787
(9 studies)
⊕⊕⊕©
moderate
Downgraded due to study
limitations (risk of bias)
and unexplained hetero-
geneity
Total cholesterol
mmol/L
The mean change in total
cholesterol ranged across
control groups from -1.6
mmol/L to 0 mmol/L
The mean change in to-
tal cholesterol in the in-
tervention groups was on
average a -0.75 mmol/L
(-1.05 to -0.46) greater
reduction compared with
control
5569
(9 studies)
⊕⊕©©
low
Downgraded due to study
limitations (risk of bias)
, unexplained heterogene-
ity, and funnel plot asym-
metry
LDL cholesterol
mmol/L
The mean change in LDL
cholesterol ranged across
control groups ranged
from
-1.4 mmol/L to -0.04
mmol/L.
The mean change in LDL
cholesterol in the inter-
vention groups was on
average a
-0.81 mmol/L (95% CI
-1.09 to -0.53) greater
reduction compared with
control
5365
(8 studies)
⊕⊕⊕©
moderate
Downgraded due to study
limitations (risk of bias)
and unexplained hetero-
geneity
Discontinuation for any
reason
6 weeks to 15 months
Total RR = 1.26 [1.02, 1.55] 2423
(6 studies)
⊕⊕©©
low
Downgraded due to study
limitations (risk of bias)
and difficulty in assessing
indirectness of evidence
120 per 1000 140 per 1000
(122 to 186)
*The basis for the assumed risk (e.g. the median control group risk across studies) is the outcomes of the study control arms. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CVD = cardiovascular disease;
CI: confidence interval; RR: risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is a principal cause of death world-
wide. In 2010, more than 17 million deaths globally were at-
tributed to CVD, over 80% of which occurred in low and middle-
income countries (WHO 2010 (a)). Furthermore, the situation is
not expected to improve, with global CVDmortality estimated to
increase by six million over the next 20 years (WHO 2010 (a)).
Ischaemic heart disease and cerebrovascular diseases, the major
CVDs, are also major causes of disability resulting in 130 million
disability-adjusted life years (DALYs) lost in 2010 (WHO 2011).
Therefore, preventing deaths and disease due to CVD is a priority
for global public health.
Optimising modifiable risk factors reduces CVD mortality and
morbidity (Cowie 2005). Individuals with both hypertension and
dyslipidaemia have a greater risk ofCVDthan thosewith either hy-
pertension or dyslipidaemia alone (Neaton 1992; Thomas 2002),
highlighting the importance of considering overall CVD risk as
opposed to individual risk factors (Perk 2012). Therefore, adopt-
ing a multi-factorial approach to CVD risk management, where
multiple risk factors are modified simultaneously, is a more ef-
fective way of reducing CVD events than focusing on single risk
factors in isolation (Gaede 2003).
Current national and international approaches toCVDprevention
incorporate both primary and secondary prevention (Perk 2012;
NICE 2010). Primary prevention aims to prevent CVD events
in those who have no clinical evidence of CVD. To achieve this,
guidelines recommend intervening when the 10 year risk for any
CVD event when the 10 year risk exceeds recommended thresh-
olds or when the risk of a fatal CVD event is estimated to be at
5% using validated risk scores (NICE 2008; NICE 2010; Perk
2012; Stone 2013). CVD incidence and mortality are reduced by
antihypertensives (Collins 1990) and statins, which improve the
lipid profile (Taylor 2013). Secondary prevention requires blood
pressure control, cholesterol lowering, and use of antiplatelet drugs
to prevent further CVD events, which is known to be effective
(ATT-Collaboration 2002; Baigent 2005; Rashid 2003).
The same CVD risk factors operate globally (Yusuf 2004) mak-
ingmulti-factorial prevention strategies relevant, but conventional
approaches targeting high risk individuals, conducting investiga-
tions, prescribing various medications, regular monitoring, and
drug dose titration to optimise CVD risk factors are difficult to
implement. Three major issues arise for global CVD prevention.
(i) Reducing risk factors in a selected high risk group does not
yield as much benefit to a population as reducing risk factors in
the whole population (Cooney 2009; NICE 2010).
(ii) Lipid-lowering with statins reduces CVD events at pre-treat-
ment lipid levels that are considered normal (Colhoun 2004;
HPSCG 2002; O’Keefe 2004; Sever 2003) making blood testing
for lipid levels less relevant and potentially increasing the number
of people who would benefit from statins.
(iii) Implementing conventionalCVDpreventionwould be a chal-
lenge for the healthcare systems in most low and middle-income
countries due to financial and time costs, human resource avail-
ability, laboratory capacity, drug acquisition, and adminstration.
Therefore, alternative and complementary population-wide strate-
gies are required.
Description of the intervention
A fixed-dose combination pill was proposed in 2001 by a World
Health Organization (WHO) and Wellcome Trust expert group
(WHO 2002) and was subsequently specified as a combination of
four drugs (beta-blocker, angiotensin converting enzyme (ACE)-
inhibitor, aspirin, and statin), whichwas estimated to reduce CVD
events by 75% in people with clinical evidence of CVD (Yusuf
2002). This concept was followed in 2003 by a proposed Polyp-
ill® (a combination of folic acid, aspirin, three low-dose antihy-
pertensives, and a low-dose statin), which was intended for both
secondary prevention and primary prevention in all people aged 55
years and over and was estimated to reduce CVD events by about
80% (Wald 2003). Recent evidence has indicated that the effects
of fixed-dose combination treatment may be less than was initially
proposed, but that this strategy may improve the blood pressure
and lipid profile to near expected levels (PILL-collaborative 2011;
TIPS 2009). The controversial aspect of the Polypill® was that it
was intended to be used at a population level without screening
of blood cholesterol or blood pressure (Wald 2011) because an
age threshold of 55 years and above would be used to determine
eligibility for treatment (Lonn 2010; Wald 2003).
While aspirin is indicated for secondary prevention of CVD, the
use of aspirin for primary prevention of CVD is generally indicated
when the absolute risk of cardiovascular disease outweighs the risk
of severe bleeding (Baigent 2009). Also, doubt exists regarding
folic acid since recent large randomised trials have indicated no
CVD benefit (Armitage 2010; Holmes 2011). On the other hand,
statins and antihypertensives as single treatments are known to
be relatively safe and individually beneficial in terms of reducing
CVD risk and thereby cardiovascular events for both secondary
prevention andprimary prevention (ALLHAT-investigators 2002;
Colhoun 2004; CTT 2012; HPSCG 2002; Julius 2004; Kearney
2008; LaRosa 2005; Ostergren 2008; Papademetriou 2003; Sever
2003; Taylor 2013; Turnbull 2003). Therefore, although uncer-
tainty exists regarding possible components, the consensus is that
the ideal fixed-dose combination therapy for primary and sec-
ondary CVDprevention should include at least one antihyperten-
sive and one statin.
There is some recent evidence regarding the efficacy and safety of
antihypertensives and statins when administered concomitantly
(Messerli 2006; Preston 2007), and of multiple antihypertensives
when administered as a single tablet (Gupta 2010; Bangalore
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2007). Clinicians may be wary of combination therapy due to the
potential restrictions on individualised management (Viera 2011);
that is, the ability to amend standard therapy because of medical
history or adverse events, such as avoiding a beta-blocker in an
asthmatic or changing from an ACE-inhibitor due to cough, and
because of the inability to titrate each drug prescribed according to
clinical response (Lonn 2010). It is also unclear if there are unique
adverse events associated with fixed-dose combination therapy be-
yond the individual components.
How the intervention might work
The effectiveness of the drugs comprising a fixed-dose combina-
tion are generally well understood, and the principles behind using
pharmacotherapy at a population level are that the drugs them-
selves are inexpensive, simple to administer for easier clinical de-
cision making, might not require a medically trained practitioner,
and may provide a more effective option that the promotion of
lifestyle changes formultiple risk factor control. Yet convincing ev-
idence of the benefits of such interventions has not been achieved.
(Beaglehole 2011; Ebrahim 2011; Lonn 2010). Althoughmodify-
ing national health policy has been successful in some high-income
countries, such as in Scandinavia (Vartiainen 2010), population-
level pharmacotherapy can be politically challenging in both high
and low to middle-income countries (Lonn 2010; Yusuf 2011)
and may not meet with patient approval. However, patient adher-
ence to the fixed-dose combination therapy is expected to be better
than with multiple tablets, but it has been argued that they will
likely have a greater potential for adverse effects than behavioural
or lifestyle changes and that a purely biological approach is too
narrow to allow the social, economic, and behavioural complexi-
ties of CVD prevention to be appreciated and confronted (Franco
2004).
Recent global epidemiological data from the Prospective Urban
Rural Epidemiology (PURE) Study investigators indicate that the
overall use of secondary prevention medication was less than 30%
and that levels of use are particularly poor in low and middle-
income countries and in rural regions (Yusuf 2011). The likely
result is inadequate prevention of further CVD events. Prescribing
fixed-dose combination therapy to individuals who are above an
accepted absolute risk threshold for initiation of pharmacotherapy
for primary CVD prevention may help to resolve these challenges.
However, fixed-dose combination therapy still has many un-
knowns. These include (i) the best constituents, whether two or
three or four or five drugs are required; and (ii) evidence of sa-
fety, effectiveness, and cost-effectiveness, and whether increasing
the number of constituents will produce a favourable risk-benefit
profile and be worth the increased cost. In particular, the evidence
is sparse concerning benefits and risks of fixed-dose combination
therapy for primary prevention in those people with low CVD
risk. Several authors have questioned whether a fixed-dose com-
bination strategy may have unforeseen negative effects on other
aspects of CVD risk reduction, for example, individuals neglect-
ing to exercise because of a sense of CVD security with fixed-dose
combination therapy (Lonn 2010). As yet there are limited long-
term follow-up outcome and safety data, which is of particular im-
portance beacuse the Polypill® concept was designed with long-
term use of fixed-dose combination therapy in mind.
Why it is important to do this review
Various fixed-dose combination pills are now beingmanufactured,
and there is evidence that physicians are aware of this option and
are potentially willing to prescribe it, though perhaps not without
some reservations (Viera 2011). There is an emerging literature of
randomised controlled trials comparing fixed-dose combination
therapy with placebo or standard practice in both the primary
and secondary prevention of CVD, as well as in assessing safety
and tolerability (Elley 2012). Since the publication of this review
(Elley 2012), additional fixed-dose combination trial data have
been published.
O B J E C T I V E S
To determine the effectiveness of fixed-dose combination therapy
on reducing fatal and non-fatal CVD events and on improving
CVD risk factors for both primary and secondary prevention of
CVD. We also aimed to determine discontinuation rates, adverse
events, health-related quality of life, and costs of fixed-dose com-
bination therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT).
Types of participants
Adults 18 years and older with no restriction regarding presence
of CVD.
Types of interventions
A fixed-dose combination therapy, a combination of several active
components into a single pill with the aim being to optimise CVD
risk and reduce CVD fatal and non-fatal events. At least one statin
and one antihypertensive agent should be included. We examined
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different combinations and doses in stratified analyses, where pos-
sible.
Trials were considered where the comparison group was usual care,
placebo, or a single drug comparator.
Types of outcome measures
Primary outcomes
• Clinical outcomes including mortality (cardiovascular and
all-cause); non-fatal CVD endpoints such as myocardial
infarction, coronary artery bypass grafting (CABG),
percutaneous transluminal coronary angioplasty (PTCA), angina
or angiographically defined ischaemic heart disease, stroke,
transient ischaemic attack (TIA), carotid endarterectomy, or
peripheral arterial disease (PAD).
• Adverse events including overall rates of discontinuation,
proportion of participants experiencing specific symptoms or
results and rates of discontinuation by specific symptoms. These
included but were not limited to: myalgias, cough, elevated liver
enzymes, gastric irritation or dyspepsia.
Secondary outcomes
• Systolic and diastolic blood pressure
• Total and LDL cholesterol
• Adherence
• Health-related quality of life, measured according to any
well validated and adjusted scale concerning quality of life
• Costs of fixed-dose combination therapy
Search methods for identification of studies
Electronic searches
The following electronic databases were searched:
• Cochrane Central Register of Controlled Trials
(CENTRAL, Issue 6, 2013) on The Cochrane Library;
• MEDLINE (Ovid) (1946 to week 2 July 2013);
• EMBASE (Ovid) (1980 to Week 28 2013);
• ISI Web of Science (1970 to 19 July 2013);
• Database of Abstracts of Reviews of Effects (DARE),
Health Technology Assessment Database (HTA), and Health
Economics Evaluations Database (HEED) in The Cochrane
Library (2011, Issue 4).
The searches were limited to records published since 2000. The
fixed-dose combination therapy was conceptualised in 2001, so
relevant trials will only appear after this date. The searches were
initially run in January 2012 (Appendix 1) and updated in July
2013 (Appendix 2). The latest searches utilised limits to core clini-
cal journals inMEDLINE and priority journals in EMBASE. The
Cochrane sensitive-maximising RCT filter (Lefebvre 2011) was
used for MEDLINE and adaptations of it were used for EMBASE
and Web of Science.
Searching other resources
We searched the metaRegister of
controlled trials (mRCT) (www.controlled-trials.com/mrct), clin-
icaltrials.gov (www.clinicaltrials.gov), and the World Health Or-
ganization (WHO) International Clinical Trials Registry Platform
(ICTRP) (http://apps.who.int/trialsearch/) for ongoing trials on
11 July 2011. This search was updated on 24 December 2011 to
review existing ongoing studies that had been identified and iden-
tify any recent registrations. In addition, reference lists of reviews
and retrieved articles were checked for additional studies and cita-
tion searches performed on key articles. Experts in the field were
contacted for unpublished and ongoing trials. Authors were con-
tacted where necessary for additional information.
Data collection and analysis
Selection of studies
From the searches, the title and abstract of each paper were re-
viewed by three authors (AdeC,MF, NW) and potentially relevant
references retrieved. Following this initial screening, the full text
reports of potentially relevant studies were obtained, and three au-
thors (AdeC, MF, NW) independently selected studies to be in-
cluded in the review using predetermined inclusion criteria. The
rapid review search was completed by one author (MH). In all
cases disagreements about any study inclusions were resolved by
consensus, and a fourth author (KR) was consulted if disagree-
ment persisted.
Data extraction and management
Data were extracted independently by two authors (AdeC, MF)
using a proforma, and principal investigators were contacted to
provide additional relevant information where necessary. Data ex-
traction from the rapid reviewwas performedby one author (MH).
Details of the study design, participant characteristics, study set-
ting, intervention and comparator, and outcome data including
details of outcome assessment, adverse effects, andmethodological
quality (randomisation, blinding, attrition) were extracted from
each of the included studies. Disagreements about extracted data
were resolved by consensus, and a third author was consulted if
disagreement persisted (KR).
Assessment of risk of bias in included studies
Risk of bias was assessed according to the Cochrane risk of bias
assessment tool, including examining the quality of the random
9Fixed-dose combination therapy for the prevention of cardiovascular disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sequence generation and allocation concealment, description of
dropouts and withdrawals (including intention-to-treat analy-
sis), blinding (participants, personnel, and outcome assessment),
and selective outcome reporting (Higgins 2011). For cluster ran-
domised trials, we have followed the Cochrane Handbook for Sys-
tematic Reviews of Interventions recommendations for assessing risk
of bias, with particular attention across the domains of: recruit-
ment; baseline imbalances; loss of clusters; incorrect analyses; and
comparability with individually randomised trials (Higgins 2011).
The risk of bias in the included studies was assessed independently
by three authors (AdeC, MF, MH).
Measures of treatment effect
Data were processed in accordance with the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Dichoto-
mous outcomes were expressed as relative risks, and 95% confi-
dence intervals (CI) were calculated for each study. For continuous
variables, net changes were compared (that is intervention group
minus control group differences) and a weighted mean difference
(MD) and 95%CI were calculated for each study. For TIPS 2009,
we compared the effects of fixed-dose combination therapy on
mean (SD) levels of blood pressure and cholesterol against the
study arms without active components as reported by the study
authors. Where SDs were not reported in the outcomes of interest
(TIPS 2009), we used baseline SDs per Elley 2012 and Furukawa
2006.
Assessment of heterogeneity
For each outcome, tests of heterogeneity were carried out using the
Chi2 test of heterogeneity and the I2 statistic. Where no or min-
imal heterogeneity was present, we performed fixed-effect model
meta-analyses. Where substantial heterogeneity was detected (I2
> 50%), we evaluated the results for possible explanations (for
example participants and interventions) and performed random-
effect model meta-analyses with cautious intepretation.
Subgroup analysis and investigation of heterogeneity
If there were sufficient studies, we aimed to conduct the following
subgroup analyses.
• Age.
• Sex.
• Primary prevention (populations where 10% or less had
pre-existing CVD) versus secondary prevention (population
where > 10% had pre-existing CVD).
• Two-drug versus three-drug or more fixed-dose
combination therapies.
• Comparator group as usual care versus placebo or inactive
control.
The first four of these analyses were pre-specified in our protocol,
and the last subgroup analysis was performed post hoc. Data were
available to perform subgroup analyses on the latter three analyses.
Sensitivity analysis
Sensitivity analyses were performed by excluding studies at high
risk of bias. We created funnel plots and performed tests of asym-
metry (Egger 1997) according to the available outcomes of systolic
blood pressure and total cholesterol to assess possible publication
bias through funnel plot asymmetry.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The searches in 2012 generated 9731 hits and 5067 papers after
de-duplication. Screening the titles and abstracts identified 41 pa-
pers for formal inclusion or exclusion. Of these, eight RCTs (eight
papers, three abstracts) met the inclusion criteria. We identified
five ongoing trials (FOCUS 2011; IMPACT 2011; Kanyini-GAP
2010; Merat 2010; PolyIran 2010). The search in 2013 gener-
ated 287 hits and 278 papers after de-duplication. Screening titles
and abstracts identified 16 papers for formal inclusion or exclu-
sion. None of these studies met the inclusion criteria. We further
identified one paper published after the latest search (UMPIRE
2013) through communication with the study authors. The study
flow diagram is presented in Figure 1. One study was a cluster
randomised trial (CRUCIAL 2011), one study was a randomised,
cross-over design clinical trial (Wald 2012), and the remaining
seven were individual-level randomised trials.
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Figure 1. Study flow.
Included studies
Details of the methods, participants, intervention, comparison
group and outcome measures for each of the studies included in
the review are shown in the Characteristics of included studies ta-
ble. Nine trials were included with 7047 participants randomised.
The three largest trials (CRUCIAL 2011; TIPS 2009; UMPIRE
2013) randomized 5518 (78%) of all participants. The duration
of the intervention and follow-up periods was generally short-
term (six weeks in one study (TOGETHER 2010), eight weeks
in one study (CUSP 2009), 12 weeks in four studies (PILL 2011;
Soliman 2009; TIPS 2009; Wald 2012)), but three studies had
median follow-up periods of 12 to 15 months (CRUCIAL 2011;
Malekzadeh 2010; UMPIRE 2013). All trials reported changes
in blood pressure and cholesterol, whereas mortality was only re-
ported in two trials (CRUCIAL 2011; UMPIRE 2013). Three tri-
als (CRUCIAL 2011; Soliman 2009; UMPIRE 2013) compared
fixed-dose combination therapy against usual care, whereas the
other six trials compared combination therapy against either ac-
tive control or placebo. One trial (TIPS 2009) included nine arms
with different drug combinations, which led to restricting our
analyses to comparisons between fixed-dose combination therapy
and groups without either blood pressure or cholesterol lowering
drugs (depending upon the analysis) and lowered the sample sizes
in these analyses.
The included studies frequently had complex inclusion and exclu-
sion criteria that were generally based upon freedom from prior
cardiovascular disease, an age threshold ranging from > 21 years to
> 55 years in women, a composite measure of short-term (10 year)
risk (five year predicted Framingham CVD risk ≥ 7.5% in PILL
2011), or one to three elevated cardiovascular disease risk factors.
UMPIRE 2013 specifically enrolled participants with established
CVDor a five year risk of CVD≥ 15%,while CRUCIAL 2011 in-
cluded > 18% of particpants with peripheral artery disease (PAD)
and > 14% with prior transient ischaemic attack (TIA) or stroke.
The participants were generallymiddle-aged with amean (SD) age
ranging from 52.6 (9.6) years (CUSP 2009) to 62.1 (10.4) years
(UMPIRE 2013). The majority of trials enrolled predominantly
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menwith two trial randomising more then 80%men (PILL 2011;
UMPIRE 2013) compared with one trial that enrolled only 27%
men (Soliman 2009). Baseline systolic blood pressure ranged from
125 mmHg to 166 mmHg, and baseline total cholesterol ranged
from 4.2 to 6.1 mmol/L.
The drugs included in the various fixed-dose combinationpills var-
ied (Table 1) with three studies including two drugs (CRUCIAL
2011; CUSP 2009; TOGETHER 2010), five studies including
four drugs (PILL 2011; Soliman 2009; Malekzadeh 2010, Wald
2012; UMPIRE 2013), and one study including five drugs (TIPS
2009). Aspirin was included in five studies (Malekzadeh 2010;
PILL 2011; Soliman 2009; TIPS 2009; UMPIRE 2013), and
blood pressure and cholesterol lowering drugs were included, by
definition, in all nine studies. The blood pressure components in-
cluded either a calcium channel blocker, thiazide diuretic, beta-
blocker, ACE-inhibitor, or angiotensin receptor blocker (ARB),
or a combination thereof. In terms of lipid lowering drugs, sim-
vastatin was used in five trials (PILL 2011; Soliman 2009; TIPS
2009; Wald 2012; UMPIRE 2013), and atorvastatin was used
in four trials (CRUCIAL 2011; CUSP 2009; Malekzadeh 2010;
TOGETHER 2010).
Excluded studies
Details and reasons for exclusion for the studies that most closely
missed the inclusion criteria are presented in the Characteristics
of excluded studies table. The majority of excluded studies were
not RCTs.
Risk of bias in included studies
Details are provided for each of the included studies in the risk of
bias tables in Characteristics of included studies and in Figure 2
and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
The methods of random sequence generation and allocation con-
cealment were unclear in three of the included studies (CRUCIAL
2011; CUSP 2009; Soliman 2009). In the six studies where ran-
domisation and allocation concealment were clear, the methods
usedwere judged tohave a low risk of bias (Malekzadeh 2010; PILL
2011; TIPS 2009; TOGETHER 2010; Wald 2012; UMPIRE
2013).
Blinding
Three of the nine included studies had a high risk for performance
bias because the comparator group was usual care (CRUCIAL
2011; Soliman 2009; UMPIRE 2013). However, one of these
studies included blinded outcome assessment (UMPIRE 2013)
and had low risk of detection bias. The remaining six trials stated
that they were double blinded (participants and study personnel,
including outcome assessors, were blinded to treatment allocation)
and were regarded as having low risk of bias in this domain.
Incomplete outcome data
Most studies reported losses to follow-up but there were differ-
ences in the proportion of losses to follow-up between the in-
terevention and control arms. Two studies had a high risk of attri-
tion bias (CRUCIAL 2011; TOGETHER 2010), including use of
last observation carried forward for missing continuous variables.
Four studies had an unclear risk of attrition bias (CUSP 2009;
Malekzadeh 2010; Soliman 2009; TIPS 2009), and three stud-
ies had low risk of attrition bias (Malekzadeh 2010; Wald 2012;
UMPIRE 2013).
Selective reporting
The risk of bias associated with selective reporting was low in
five studies (CUSP 2009; Malekzadeh 2010; Soliman 2009; TIPS
2009; UMPIRE 2013), unclear in three studies (CRUCIAL 2011;
TOGETHER 2010; Wald 2012), and high in one study (PILL
2011).
Other potential sources of bias
In CRUCIAL 2011, different doses of fixed-dose combination
therapy were used among participants randomised to the inter-
vention arm, which was associated with an uncertain risk of bias
because the option for drug titration could attenuate the effect size
if investigators did not titrate the dose of fixed-dose combination
therapy; conversely, the differential dosing could accentuate the
effect size because of higher drug doses. In Malekzadeh 2010, a
run-in period was used to exclude potential participants who had
adherence rates < 70%. In Soliman 2009, participants had varying
degrees of background blood pressure and lipid lowering therapies
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between groups. In other cases there was insufficient information
to judge the risk of bias in other sources of bias not covered above,
and all were categorised as unclear. In UMPIRE 2013, participants
randomised to the intervention arm received fixed-dose combina-
tion therapy at no cost compared with participants randomised to
usual care who were responsible for their drug costs, which may
have led to increased adherence in the intervention arm.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
All-cause mortality
Two studies (CRUCIAL 2011; UMPIRE 2013) reported death
rates at the end of the study period with follow-up at 12 and
15 months, respectively. Mortality rates were low in both groups
(1.2% in the intervention group compared with 1.0% in the com-
parator group), and participants randomised to the intervention
had no evidence of increased mortality compared with the com-
parator group (RR 1.26, 95% CI 0.67 to 2.38) (Analysis 1.1) in
the context of relatively few events. Both studies included > 10%
of participants with prevalent CVD and both studies included
usual care as the comparator group, so no subgroup analyses could
be performed in these domains. The results were similar when re-
stricting this analysis to UMPIRE 2013, which included a fixed-
dose combination intervention with four components (compared
with two in CRUCIAL 2011) (data not shown).
Major CVD events
Only two out of nine studies (Malekzadeh 2010; UMPIRE 2013)
reported rates of cardiovascular events. Cardiovascular events were
uncommon in both groups (4.0% rate in the intervention group
compared with 2.9% in the comparator group), and participants
randomised to the intervention had no evidence of increased event
rates compared with the comparator group (RR 1.38, 95% CI
0.91 to 2.10) (Analysis 1.2).However, these results were imprecise,
and there was only one event reported in both arms ofMalekzadeh
2010. Participants in Malekzadeh 2010 did not have prevalent
CVD, and the comparator group received placebo, compared with
the participants in UMPIRE 2013. Both trials included four-drug
fixed-dose combination therapy.
Adverse events
Seven trials including 4864 participants reporting aggregated rates
of adverse events in both groups were included in the meta-anal-
ysis. The risk for adverse events was higher in participants in the
intervention arm compared with participants in the control arm
(30% versus 24%, RR 1.19, 95% CI 1.09 to 1.30) (Analysis 1.3).
Specific side effects that were evaluated included myalgias (five
studies, 12% versus 11%, RR 1.14, 95% CI 0.81 to 1.60), in-
creased liver enzymes (three studies, 8% versus 7%, RR 1.01, 95%
CI 0.72 to 1.43), cough (four studies, 6% versus 3%, RR 2.34,
95%CI0.77 to 7.08), gastric irritation anddyspepsia (four studies,
3% versus 2%, RR 1.33, 95%CI 0.66 to 2.74), and bleeding (one
study, 2% versus 0.5%, RR 4.00, 95% CI 0.45 to 35.46). Results
were similar after excluding trials with >10% of participants with
prevalent CVD or usual care as the comparator group (CRUCIAL
2011; UMPIRE 2013 for both) (RR 1.36, 95% CI 1.16 to 1.60)
and after excluding trials with less than three drug combinations
(CRUCIAL 2011; CUSP 2009; TOGETHER 2010) (RR 1.31,
95% CI 1.13 to 1.51). Rates of discontinuation were reported in
both groups in the six trials with active control or placebo as the
comparator and were higher in participants randomised to fixed-
dose combination therapy (14% versus 11.5%, RR 1.26, 95% CI
1.02 to 1.55) (Analysis 4.1).
Secondary outcomes
Blood pressure
All nine trials reported changes in systolic and diastolic blood pres-
sure in 5787 participants. There was a large degree of heterogene-
ity among the trials for both systolic blood pressure (I2 = 92%) and
diastolic blood pressure (I2 = 91%). No single trial explained this
heterogeneity, nor was it explained by primary versus secondary
prevention trials nor two-drug versus three ormore drug combina-
tions. Using a random-effects model, the WMD in systolic blood
pressure between the intervention and control arms was -7.02
mmHg (95% CI -10.18 to -3.87) (Analysis 2.1), and the WMD
in diastolic blood pressure between the intervention and control
armswas -3.65mmHg (95%CI -5.44 to -1.85) (Analysis 2.2). Tri-
als that included usual care in the comparator group (CRUCIAL
2011; CUSP 2009; UMPIRE 2013) did not have as large reduc-
tions in systolic blood pressure (MD -4.76 mmHg, 95% CI -
11.24 to -1.71) compared with other trials (Analysis 2.5). These
results should be interpreted with caution given the degree of het-
erogeneity. There was no evidence of funnel plot asymmetry for
systolic blood pressure.
Lipids
All nine trials reported changes in total cholesterol in 5569 partici-
pants, and eight trials reported changes in LDL cholesterol in 5365
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participants. There was a large degree of heterogeneity among the
trials for both total cholesterol (I2 = 97%) and LDL cholesterol
(I2 = 97%). No single trial explained this heterogeneity, nor was
it explained by primary versus secondary prevention trials, nor
two-drug versus three or more drug combinations. Using a ran-
dom effects model, the weightedmean difference (WMD) in total
cholesterol between the intervention and control arm was -0.75
mmol/L (95% CI -1.05 to -0.46) (Analysis 3.1). Using a random-
effects model, WMD in LDL cholesterol between the interven-
tion and control arms was -0.81 mmol/L (95% CI -1.09 to -0.53)
(Analysis 3.2). Trials that included usual care in the comparator
group (CRUCIAL 2011; CUSP 2009; UMPIRE 2013) did not
have as large reductions in total cholesterol (MD -0.28 mmol/L,
95% CI -0.66 to 0.10) compared with other trials (Analysis 3.5).
These results should be interpreted with caution given the degree
of heterogeneity. There was evidence of funnel plot asymmetry for
total cholesterol (Figure 4).
Figure 4. Funnel plot of comparison: 3 Cholesterol, outcome: 3.1 Total cholesterol.
Adherence
In trials with usual care comparisons, assessing adherence or dis-
continuation was problematic. In fact, only one (UMPIRE 2013)
out of three trials that included a usual care arm reported ad-
herence, which was defined as taking aspirin, statin, and two or
more blood pressure lowering drugs at least 4 days per week. In
UMPIRE, adherence at 15 months was 86% in the intervention
group compared with 65% in the comparator group (RR = 1.33
[95% CI: 1.26, 1.41]). However, the discontinuation rate among
individuals randomized to fixed-dose combination was 22%.
Health-related quality of life
One trial (UMPIRE 2013) reported health-related quality of life
measures at the end of the study period using the EQ-5D instru-
ment. Mean (SD) summary index scores were similar between
the intervention and comparator groups (0.82 (0.01) versus 0.81
(0.1), P = 0.43).
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Costs
No studies have reported costs or cost-effectiveness associated with
fixed-dose combination therapy to date.
D I S C U S S I O N
Summary of main results
The trials included in this systematic review demonstrated no dif-
ferences in mortality and cardiovascular events between partici-
pants randomised to the fixed-dose combination group compared
with comparator groups. However, the event rates for these out-
comes were low so they were relatively uncommon, only two out
of nine trials reported these outcomes, and these trials included at
least one domain that had a high risk of bias, suggesting that these
results should not viewed with confidence. Adverse events were
common in both the intervention (30%) and comparator (24%)
groups, with participants randomised to fixed-dose combination
therapy being 20% (95% CI 9% to 30%) more likely to report an
adverse event. Notably, no serious adverse events were reported.
The trials reported weighted mean reductions in systolic (-7.02
mmHg, 95% CI -10.18 to -3.87) and diastolic blood pressure (-
3.65 mmHg, 95% CI -5.44 to -1.85) and total (-0.75 mmol/L,
95%CI -1.05 to -0.46) and LDL cholesterol (-0.81 mmol/L, 95%
CI -1.09 to -0.53). However, there was substantial heterogeneity
in these estimates, which should be interpreted with caution. The
trials demonstrated a 26% (95% CI 2% to 55%) increased risk
of discontinuing the study medication (discontinuation rate range
10% to 23%) compared with either usual care, placebo, or a sin-
gle drug (aspirin, statin, or thiazide in the case of TIPS 2009).
We were unable to explain the heterogeneity of effects on blood
pressure or lipids in terms of primary versus secondary prevention
trials, the number of drugs in the fixed-dose combination pills, or
the comparator group being active control, placebo or usual care.
It is possible that the heterogeneity is due to the characteristics of
the patients studied, differences in the potency of the antihyper-
tensives and statins used, and the differences in treatments used
in the comparison groups.
Overall completeness and applicability of
evidence
The included trials used five different polypills: three of the stud-
ies (CRUCIAL 2011; CUSP 2009; TOGETHER 2010) included
polypills with only two drugs (one blood pressure lowering drug
(amlodipine) and one statin (atorvastatin)); three studies (PILL
2011; Soliman 2009; UMPIRE 2013) used the Dr Reddy’s Lab
Red Heart Pill that includes four drugs (aspirin, lisinopril, sim-
vastatin, and hydrochlorothiazide), and the remaining studies in-
cluded different four-drug (Malekzadeh 2010;Wald 2012) or five-
drug combinations (TIPS 2009). The decision to combine the
estimates of these different drug combinations and different com-
parators wasmade andmeta-analysis for this reviewwas performed
to evaluate the estimated effect size of fixed-dose combination
therapy. A rationale for fixed-dose combination therapy is that it is
more likely to be taken than multiple dose regimens. However, we
found a higher likelihood of discontinuation for fixed-dose treat-
ment than for placebo. Comparisons of adherence across trials are
hampered by differing definitions, which should be standardised
in future reporting of these trials. Trials using ’usual care’ com-
parison groups have reported reasonably high levels of adherence
and low levels of discontinuation, but these may be misleading as
there is no relevant comparison.
There are six ongoing trials (FOCUS 2011; IMPACT 2011;
Kanyini-GAP 2010; Merat 2010; PolyIran 2010; TIPS-3 2012),
including three that are part of the Single Pill Against Cardio-
vascular Events (SPACE) collaboration. These results are likely to
have an important impact on our confidence in the estimate of
effect and may change the estimate.
Quality of the evidence
Our review was limited by the presence of a moderate to high
risk of bias in the domains of selection, performance, detection,
attrition, and other types of bias in five of the nine trials that were
included, which limits the confidence with which we have in these
results. Using other GRADE domains, the quality of evidence was
also limited by the imprecision of results for the effects on all-
cause and CVD mortality, the heterogeneity of effects on blood
pressure and cholesterol, and funnel plot asymmetry suggestive of
publication bias (total cholesterol only). Indirectness of evidence
was further limited in evaluating the effects of fixed-dose combi-
nation on adverse events and discontinuation rates, particularly
because these comparisons excluded participants receiving ’usual
care’ (because these groups cannot ’discontinue’ usual care). How-
ever, these comparisons are likely very relevant in assessing the
overall effect of fixed-dose combination therapy.
Potential biases in the review process
For the TIPS 2009 and Wald 2012 studies, we relied upon the
point estimates and standard deviations extracted by Elley 2012,
since these data points were not specifically provided in the text
of the manuscripts or by the study authors. Elley and colleagues
estimated the outcome standard deviations using baseline standard
deviations as reported by Furukawa and colleagues (Furukawa
2006).
Agreements and disagreements with other
studies or reviews
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Our results demonstrated modestly lower reductions in systolic (-
7.02 mmHg versus -9.20 mmHg) and diastolic blood pressure (-
3.65 mmHg versus -5.00 mmHg) and lower total (-0.75 mmol/L
versus -1.22 mmol/L) and LDL cholesterol (-0.81 mmol/L versus
-1.02 mmol/L) compared with an earlier systematic review (Elley
2012). The absolute and relative adverse event rates were similar
to those reported by Elley 2012, but the absolute and relative
discontinuation rates were lower in our review. These differences
are accounted for by our inclusion of three additional studies (
CRUCIAL 2011; Soliman 2009; UMPIRE 2013).
The changes in blood pressure were lower than those predicted
by Wald and Law (diastolic blood pressure: -3.65 mmHg versus -
11 mmHg), which may be due to the use of one blood pressure
lowering drug in three of the studies (CRUCIAL 2011; CUSP
2009; TOGETHER 2010), all of which used a calcium channel
blocker (amlodipine) rather than a combination of thiazide, ACE-
inhibitor, or beta-blocker as previously proposed (Wald 2003).
In addition, the baseline blood pressure from which Wald and
Law were operating was 150/90 mmHg (Wald 2003, Lonn 2010),
compared with a range of blood pressures of 125 to 165 mmHg/
78 to 91 mmHg, with seven of nine studies having a baseline sys-
tolic blood pressure less than 150 mmHg. The changes in LDL
cholesterol were also lower than those predicted by Wald and Law
(-0.75mmol/L versus 1.8mmol/L), likely due to differences in the
dose and type of statin used in these trials (Wald 2003). The base-
line LDL cholesterol proposed by Wald and Law was 4.8 mmol/L
(Lonn 2010), compared with a range of LDL cholesterol from 2.3
to 3.7 mmol/L with all nine studies having a mean baseline LDL
cholesterol less than 4.8 mmol/L. Three trials used simvastatin
20 mg (Soliman 2009; PILL 2011; TIPS 2009) compared with
simvastatin 40 mg proposed by Wald and Law (Wald 2003).
Bangalore and colleagues have previously performed a systematic
review and meta-analysis of the effect of fixed-dose combination
therapy on adherence for chronic conditions including hyperten-
sion, diabetes, and HIV (Bangalore 2007) and reported a 24%
(95% CI 19% to 29%) lower rate of discontinuation compared
with control. These results were similar to those reported byGupta
and colleagues, who reported an increased odds of adherence with
fixed-dose combination therapy for blood pressure compared with
usual care (OR 1.21, 95% CI 1.03 to 1.43) (Gupta 2010). Gupta
and colleagues demonstrated trends toward improved blood pres-
sure control and side effects (Gupta 2010). The differences in dis-
continuation rates and adherence between these studies and our
study may be due to the fact that patients in the Bangalore and
Gupta meta-analyses received active drug in either arm compared
with our meta-analysis where comparator group participants re-
ceived either usual care (and possibly no drugs), placebo, or al-
ternative drugs with potentially lower rates of side effects (TIPS
2009).
Virdee and colleagues interviewed 11 primary care physicians and
five practice nurses in nine Birmingham, UK practices about their
knowledge and attitudes toward fixed-dose combination therapy
(Virdee 2013). The majority of respondents were uncertain about
how they would incorporate fixed-dose combination therapy in
their practice and whether it was designed for primary or sec-
ondary CVDprevention.Most felt reluctant about using a specific
age cut-off to initiate therapy, despite acknowledging potential
advantages to this approach. Most respondents felt unease at the
concept of minimial or no monitoring of patients taking a fixed-
dose combination therapy, despite the proposal by Wald and Law
(Wald 2003). In March 2010, Viera and colleagues surveyed US
physicians about their willingness to prescribe fixed-dose combi-
nation therapy. Nearly two out of every three physicians reported
that they would prescribe fixed-dose combination therapy for pa-
tients at moderate risk for CVD and more than four out of ev-
ery five physicians reported that they would prescribe fixed-dose
combination therapy for patients at high risk for CVD. These
disparate data using different methods of data collection suggest
varying potential for uptake among physicians.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Compared with usual care, active control, or placebo for CVD
prevention, the effects of fixed-dose combination therapy on all-
cause mortality or CVD events are uncertain due to low event
rates, imprecision, and risk of bias. Participants randomised to
fixed-dose combination therapy had moderately higher rates of
adverse events (RR 1.18, 95% CI 1.09 to 1.30) and discontinu-
ation (RR 1.26, 95% CI 1.02 to 1.55). Fixed-dose combination
therapy is associated with a -7.05 mmHg (95% CI -10.18 to -
3.87) and -3.65 mmHg (95% CI -5.44 to -1.85) greater reduc-
tion in systolic and diastolic blood pressure and a -0.75 mmol/L
(95% CI -1.05 to -0.46) and -0.81 mmol/L (95% CI -1.09 to -
0.53) greater reduction in total and LDL cholesterol, but there is
substantial heterogeneity in these results. The heterogeneity may
reflect differences in primary compared with secondary prevention
studies, the composition of fixed-dose combinations, comparator
groups, or all of the above. Fixed-dose combination therapy im-
proved adherence to a multi-drug strategy by 33% (26% to 41%)
compared with usual care, but this comparison was reported in
only one study. Fixed-dose combination therapy may be an alter-
native therapy for risk factor control in patients for CVD preven-
tion but future studies will likely have an important effect on these
estimates.
Implications for research
High-quality randomised controlled trials are needed to evaluate if
the effect of fixed-dose combination therapies on risk factor levels
translates into improvements in fatal and non-fatal events in both
primary and secondary CVD prevention settings. Studies evaluat-
ing the effects of fixed-dose combination therapy compared with
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usual multiple variable dose therapies should also be performed
to compare adherence rates more directly, since discontinuation
rates are generally lower among participants receiving placebos.
Larger studies are also needed to evaluate the risk of serious adverse
events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CRUCIAL 2011
Methods Open label cluster randomised trial
Participants 136 clusters; 1461 total participants (779 intervention; 682 control participants), men
and women aged 35-79 years with hypertension and total cholesterol <250 mg/dl plus
three or more risk factors (current smoker, peripheral artery disease, type 2 diabetes,
family history of early CHD before aged 55 years in first dgree relative; left ventricular
hypertrophy on electrocardiogram [ECG]; history of transient ischemic attack or stroke
three or more months prior to screening; ECG abnormalities; age >55 years [men] or
>65 years [women], total cholesterol >250mg/dl, or HDL <40mg/dl)
Interventions Intervention: Single pill amlodipine/atorvastatin (5mg/10mg to 10mg/10mg; site inves-
tigators could request dosages of 5/20 mg and 10/20 mg) in addition to other hyper-
tensive / lipid lowering therapy as required, as well as therapeutic lifestyle counselling
change
Control: Usual care, including therapeutic lifestyle counselling change
Outcomes SBP, DBP, LDL-C, total cholesterol; all-cause mortality reported
Notes Control: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Investigators - randomly assigned”, “randomisa-
tion was stratified”, “investigator as unit of ran-
domisation”
Allocation concealment (selection bias) Unclear risk Due to cluster randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
High risk 93/779 (11.9%) discontinued intervention; 44/
682 (6.5%) discontinued in usual care arm
Selective reporting (reporting bias) Unclear risk Not all outcomes available for meta-analysis
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CRUCIAL 2011 (Continued)
Other bias Unclear risk Significant differences between two arms in terms
of baseline blood pressure and ECG abnormal-
ities/PVD; underpowered according to authors’
own calculations; different doses of intervention
were available upon request to investigators
CUSP 2009
Methods Individual-level randomised controlled trial
Participants 130 participants (66 intervention; 64 control) with coexisting, untreated hypertension
(SBP=140-169 mmHg or DBP=90-105 mmHg) and dyslipidemia (LDL-C=110-160
mg/dl) but without a history of cardiovascular disease; age >21 years
Interventions Intervention: Single pill amlodipine/atorvastatin (5mg/20mg) + therapeutic lifestyle
changes
Control: Therapeutic lifestyle changes
Outcomes Target for BP <140/90 mm Hg and LDL-C <100 mg/dL [2.59 mmol L] at week 4 and
week 8: the percentage of patients in whom the single LDL-C goal was reached at weeks
4 and 8; mean changes from baseline in SBP and DBP at weeks 4 and 8; mean changes
from baseline in LDL-C at weeks 4 and 8; 10-year Framingham risk of CHD at weeks
4 and 8
Notes Control: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specifically stated: “Patients were ran-
domised in a double-blind manner”
Allocation concealment (selection bias) Unclear risk Not specifically stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specifically stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specifically stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how data from particpants lost to
follow-up were handled
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CUSP 2009 (Continued)
Selective reporting (reporting bias) Low risk Primary outcomes reported (week 4 blood
pressure and LDL targets)
Malekzadeh 2010
Methods Block randomisation
Participants 475participants (241polypill; 234 control)without cardiovascular disease, hypertension,
or hyperlipidaemia aged 50 to 79 years (men) and 55 to 79 years (women)
Interventions Intervention: Polypill (aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg and hy-
drochlorothiazide 12.5 mg)
Control: placebo
Outcomes Hospital admissions / major cardiovascular events / seated and standing BP, LDL-C,
total cholesterol, triglycerides, HDL-C and fasting glucose
Notes Control: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated block randomisation
Allocation concealment (selection bias) Low risk Computer generation allocation to numbered list of blister packs
manufactured by Alborz Darou
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical blister packs used for participant blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors (clinicians) blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk High rate of loss to follow-up at 12 months (experimental 32%;
control 22%)
Selective reporting (reporting bias) Low risk Primary outcome reported (changes in blood pressure and LDL
cholesterol)
Other bias High risk Run-in period excluded participants with low (<70%) adher-
ence; large differences in baseline characteristics between inter-
vention and control groups
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PILL 2011
Methods Individual-level randomised controlled trial
Participants 378 participants (189 intervention; 189 control) with 5-year Framingham coronary
heart disease risk ≥7.5% or if Framingham risk was between 5% and 7.5%, two or
more additional untreated risk factors were needed (body mass index >30kg/m2, waist
circumference >102cm in men or >88cm in women; heart rate > 80 bpm; fasting glucose
5.6-7 mmol/L, triglycerides >1.7 mmol/L; family history of first degree relative with
premature ischemic heart disease or stroke (men < 55 years; women: <65 years), or
glomerular filtration rate <60ml/min
Interventions Intervention: Red heart pill (aspirin 75 mg, lisinopril 10mg, hydrochlorothiazide 12.
5mg and simvastatin 20mg)
Control: placebo
Outcomes Change in SBP; change in LDL-C; tolerability; secondary outcomes included adher-
ence,DBP, total cholesterol,HDL-C, total cholesterol:HDL cholesterol ratio, non-HDL
cholesterol, triglycerides, frequency of switching/adding open-label treatment, estimated
effects on CVD risk
Notes Control: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer based randomisation
Allocation concealment (selection bias) Low risk Central computer based randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Specifically reported and use of placebo
control
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors and study staff all
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates of loss to follow-up (experimental
2%; control 1%)
Selective reporting (reporting bias) High risk Last observation carried forward for miss-
ing data at week 12
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Soliman 2009
Methods Open label, parallel group randomised clinical trial
Participants 216 (105 Polypill; 111 control);≥40 years for men and≥50 years for women; estimated
10 year World Health Organization total cardiovascular risk score≥20% without estab-
lished cardiovascular disease
Interventions Intervention: Red Heart pill 2b (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and
12.5 mg hydrochlorothiazide)
Control: Standard practice defined by the study investigators
Outcomes SBP, total cholesterol, 10-year cardiovascular disease risk, adherence, fasting glucose,
creatinine, potassium, and liver enzymes
Notes Control: inactive/usual care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No method of randomisation stated
Allocation concealment (selection bias) High risk Open label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how missing data were handled
Selective reporting (reporting bias) Low risk Primary outcomes (blood pressure, choles-
terol, ten year CVD risk) all reported
Other bias High risk Use of non-study antihypertensives and
statins very different between centres
TIPS 2009
Methods Individual-level randomised controlled trial
Participants 2053 participants (205 aspirin; 205 thiazide; 209 thiazide + ramipril; 207 thiazide +
atenolol; 205 ramipril + atenolol; 204 thiaizde + ramipril + atenolol; 204 thiaizide +
ramipril + atenolol + aspirin; 202 simvastatin; 412 Polycap [thiazide + ramipril + atenolol
+ simvastatin + aspirin); 45 to 80 years old without prior cardiovascular disease but with
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TIPS 2009 (Continued)
at least one risk factor: type 2 diabetes; blood pressure >140/90 mmHg but <160/100
mmHg; smoker within the past five years; waist-to-hip ratio >0.85 for women and 0.90
for men; LDL cholesterol >3.1 mmol/L but less 4.5 mmol/L or HDL cholesterol <1.04
mmol/L
Interventions Intervention: Polycap (thiazide 12·5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20
mg, aspirin 100 mg)
Control: 8 other drug/drug combination groups listed above
Outcomes LDL for the effect of lipid-lowering drugs, BP for antihypertensive drugs, heart rate for
the effects of atenolol, urinary 11-dehydrothromboxane B2 for the antiplatelet effects of
aspirin, rates of discontinuation of drugs for safety
Notes Control: active
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer randomisation
Allocation concealment (selection bias) Low risk Central computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo control using identical capsule
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding reported; probably oc-
curred given research team’s prior studies
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear howmissing SBP and LDL-C data
at week 12 follow-up were handled
Selective reporting (reporting bias) Low risk Primary outcomes reported
TOGETHER 2010
Methods Individual-level randomised, double dummy controlled trial
Participants 244 participants (122 intervention; 122 control) with history of hypertension but no
history of CVD or diabetes with ≥2 risk factors: age ≥45 years for men; ≥55 years
for women; current smoker; family history of premature coronary heart disease in first
degree relative; HDL cholesterol <40 mg/dl; waist circumference >102 cm in men and
>88 cm in women
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TOGETHER 2010 (Continued)
Interventions Intervention: single pill amlodipine (5/10mg) plus atorvastatin 20mg + therapeutic
lifestyle changes
Control: amlodipine (5/10mg) + therapeutic lifestyle changes
Outcomes Proportion achieving a BP goal <140/90 mmHg and LDL-C<100 mg/dl at week 6; BP
and LDL-C goal at week 4; BP goal at weeks 4 and 6; change in SBP, DBP, LDL-C,
total cholesterol, HDL-C, triglycerides at weeks 4 and 6; predicted 10 year Framingham
coronary heart disease risk score, adverse events
Notes Control: active
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central, computer based telerandomisa-
tion
Allocation concealment (selection bias) Low risk Central, computer based telerandomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double blind labeled bottles but unclear if
pills were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reportedly double blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Last observation carried forward used for
non-completers for final analysis
Selective reporting (reporting bias) Unclear risk Primary outcomes reported
UMPIRE 2013
Methods Randomised, open label, blinded endpoint clinical trial of an FDC-based treatment
strategy compared with usual care
Participants ≥18 years old and established CVD or an estimated 5 year CVD risk of 15% or greater
in India and 3 European countries (England, Ireland, and the Netherlands)
Interventions Intervention: one of two versions of the fixed-dose combination ((1) aspirin 75mg,
simvastatin 40mg, lisinopril 10mg, atenolol 50mgor (2) aspirin 75mg, simvastatin 40mg,
lisinopril 10mg, hydrochlorothiazide 12.5mg)
Control: usual care
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UMPIRE 2013 (Continued)
Outcomes Primary: adherence to indicated medications (self-reported current use of antiplatelet,
statin, and≥2 BP-lowering therapies, defined as taking the medication for at least 4 days
during the week preceding the visit) at baseline and at the end of the trial and changes
in SBP and LDL-C from baseline to the end of the trial
Secondary: adherence at 12 months, reasons for stopping cardiovascular medications,
quality of life, serious adverse events, and changes in total cholesterol, HDL-C, triglyc-
erides, and creatinine from baseline to 12 months and end of study and cardiovascular
events (including coronary heart disease, heart failure leading to death or hospital ad-
mission, and cerebrovascular or peripheral arterial disease events)
Notes Control: inactive/usual care
Trial is part of “Single Pill Against Cardiovascular Events (SPACE)” collaboration, which
encompasses the “Improving Adherence using Combination Therapy (IMPACT)” and
“Kaniyini Guidelines Adherence with the Polypill (Kanyini-GAP)” trials
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation occurred through web-
based clinical data management system
Allocation concealment (selection bias) Low risk Randomisation occurred through web-
based clinical data management system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk At the end of the study, data on self-re-
ported adherence, systolic BP, and LDL-C
were available for 1921 (96%), 1849 (92%)
, and1807 (90%) randomizedparticipants,
respectively
Selective reporting (reporting bias) Low risk All primary outcomes reported; quality of
life outcomes were not reported in this ini-
tial report
Other bias Unclear risk Participants randomized to the interven-
tion arm received fixed-dose combination
therapy at no cost compared with partici-
pants randomized to usual care who were
responsible for their drug costs
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Wald 2012
Methods Individual-level randomised double-blind placebo-controlled cross-over trial
Participants 86 individuals (43 Polypill then placebo; 43 placebo then Polypill) aged 50 years or over
without history of cardiovascular disease who were previously taking simvastatin and
blood pressure lowering drugs; limited to participants living in London or could travel
easily to London
Interventions Intervention: fixed-dose combination (amlodipine 2.5mg, losartan 25mg, hy-
drochlorothiazide 12.5mg, simvastatin 40mg) daily for 12 weeks
Control: placebo
Outcomes SBP, DBP, total cholesterol, LDL-C, HDL-C, triglycerides, apoB, adherence
Notes Control: inactive/placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated block randomisation
Allocation concealment (selection bias) Low risk Computer generated block randomisation
with sequential identical blister packs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors reported as being
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcomes reported
Selective reporting (reporting bias) Unclear risk Adverse event data not clearly described;
only proportion of individuals with “symp-
tom”, which was assumed to be an adverse
event
Other bias Low risk No need for intention-to-treat analysis as
cross-over design. Any losses to follow-up
clear
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Avenell 2012 Not related to cardiovascular outcomes
Bakris 2012 Did not include statin fixed-dose combination intervention
Blank 2005 Intervention fixed-dose combination therapy but not RCT
Boger-Megiddo 2010 Case-control study, not RCT
CAPABLE 2009a Intervention fixed-dose combination therapy but not RCT
CAPABLE 2009b Intervention fixed-dose combination therapy but not RCT
Chapman 2010 Intervention polypill but not RCT
Chyrsant 2011 Review article, not RCT
Derosa 2013 Did not include statin fixed-dose combination intervention
Gemini-AALA 2009 Intervention fixed-dose combination therapy but not RCT
JEWEL 2006 Intervention fixed-dose combination therapy but not RCT
JEWEL 2006a See above
Li 2011 Non-randomized, non-comparator study
Liew 2009 Intervention fixed-dose combination therapy but not RCT (cost-effectiveness analysis)
Neldam 2012 Not RCT
Neutel 2012 Not RCT
Nitsch 2013 NSAID coprescription, not RCT
Patel 2010 Intervention fixed-dose combination therapy but not RCT
Sun 2012 Comparator: fixed-dose combination
TIPS-2 2012 Comparator group includes fixed-dose combination therapy
Wald review 2012 Review article, not RCT
Weber 2012 Retrospective analysis, not RCT
Weber 2013 Secondary analysis of ACCOMPLISH trial
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(Continued)
Zhu 2012 Did not include statin fixed-dose combination intervention
Characteristics of ongoing studies [ordered by study ID]
FOCUS 2011
Trial name or title FOCUS
Methods Randomised controlled trial
Participants 1340 post-MI patients followed up for 9 months
Interventions Fixed-dose combination (aspirin 100mg, ramipril 2.5mg/5mg/10mg, simvastatin 40mg) or three drugs sep-
arately
Outcomes Primary outcomes: adherence to treatment
Secondary outcomes: changes in SBP/DBP/LDL-C, adverse events, economic data
Starting date Protocol published November 2011
Contact information
Notes
IMPACT 2011
Trial name or title IMProving Adherence using Combination Therapy (IMPACT)
Methods Open-label randomised controlled trial
Participants 600 participants who have had CVD events or are at high risk of CVD followed up for 12 months
Interventions Fixed-dose combination (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg/
atenolol 50mg) or current medications
Outcomes Primary outcomes: adherence to prescribed medication, changes in SBP/LDL-C
Secondary outcomes: other serum lipids, medication dispensing, barriers to adherence, CVD events, other
serious adverse events, quality of life, prescriber acceptability
Starting date Protocol published July 2011
Contact information
Notes Linked to Kanyini-GAP and UMPIRE
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Kanyini-GAP 2010
Trial name or title Kanyini-Guidelines Adherence with the Polypill (Kanyini-GAP)
Methods Open randomised controlled trial
Participants 1000 participants at high risk of cardiovascular events recruited frommainstream GP practices and Aboriginal
health services followed up for an average of 18 months
Interventions One of two versions of fixed-dose combination (chosen by treating clinician: (1) aspirin 75mg, simvastatin
40mg, lisinopril 10mg, atenolol 50mg or (2) aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochloroth-
iazide 12.5mg) or to usual care
Outcomes Primary outcomes: change in cholesterol / SBP, self-reported use of aspirin / simvastatin / at least two
antihypertensives
Secondary outcomes: cardiovascular events, renal outcomes, self-reported barriers to indicated therapy, pre-
scription of indicated therapy, serious adverse events, changes in quality of life
Starting date Protocol published August 2010
Contact information
Notes Linked closely to IMPACT and UMPIRE
Merat 2010
Trial name or title Polypill and Nonalcoholic Steatohepatitis (PolyIran-L)
Methods Unclear in trial registration
Participants Unclear in trial registration, followed up for 5 years
Interventions Fixed-dose combination (unspecified)
Outcomes Cardiovascular events (also non-alcoholic steatohepatitis-specific outcomes)
Starting date Registered 19/11/2010 (NCT01245608)
Contact information
Notes No publication of protocol, design or any data as yet
PolyIran 2010
Trial name or title PolyIran
Methods Three-armed open randomised controlled trial
Participants 30000 participants over 50 years in Iran followed up between 2 and 5 years
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PolyIran 2010 (Continued)
Interventions Fixed-combination therapy (aspirin, statin, antihypertensives - not detailed) + minimal care; minimal care
alone; usual care alone
Outcomes Cardiovascular events, cardiovascular-specific mortality
Starting date Registered 14/12/2010 (NCT01271985)
Contact information
Notes No publication of protocol, design or any data as yet
TIPS-3 2012
Trial name or title The International Polycap Study-3
Methods 2 x 2 x 2 randomised controlled trial, factorial design (3 arms: Polycap D, aspirin, vitamin D)
Participants 5500 participants (women 60 years or older and men 55 years or older) without known heart disease or prior
stroke and without a clear indication or contraindication to any of the study medications and INTERHEART
risk score of 10 or greater
Interventions Polycap DS vs. placebo; embedded in trial comparing enteric coated aspirin vs. placebo and vitamin D vs.
placebo
Outcomes Composite of major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac
arrest, or revascularisation with evidence of ischemia in participants taking Polycap versus placebo
Starting date Protocl updated on clinicaltrials.gov on October 2012 (ClinicalTrials.gov Identifier:NCT01646437)
Contact information Dr. Salim Yusuf, Population Health Research Institute
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality, cardiovascular events, and adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 3465 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.67, 2.38]
2 Cardiovascular events 2 2479 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.91, 2.10]
3 Any adverse event 7 4864 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.09, 1.30]
Comparison 2. Blood pressure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure 9 5787 Mean Difference (IV, Random, 95% CI) -7.02 [-10.18, -3.87]
2 Diastolic blood pressure 9 5787 Mean Difference (IV, Random, 95% CI) -3.65 [-5.44, -1.85]
3 Systolic blood pressure: primary
prevention trials
7 2366 Mean Difference (IV, Random, 95% CI) -7.45 [-11.05, -3.84]
4 Systolic blood pressure: 3+ drugs
only
6 4014 Mean Difference (IV, Random, 95% CI) -7.00 [-11.40, -2.60]
5 Systolic blood pressure:
comparator as usual care
3 3624 Mean Difference (IV, Random, 95% CI) -4.76 [-11.24, 1.71]
Comparison 3. Cholesterol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol 9 5569 Mean Difference (IV, Random, 95% CI) -0.75 [-1.05, -0.46]
2 LDL cholesterol 8 5365 Mean Difference (IV, Random, 95% CI) -0.81 [-1.09, -0.53]
3 Total cholesterol: primary
prevention trials
7 2147 Mean Difference (IV, Random, 95% CI) -0.92 [-1.18, -0.65]
4 Total cholesterol: 3+ drugs only 6 3796 Mean Difference (IV, Random, 95% CI) -0.65 [-1.10, -0.21]
5 Total cholesterol: comparator as
usual care
3 3624 Mean Difference (IV, Random, 95% CI) -0.28 [-0.66, 0.10]
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Comparison 4. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Discontinuation of study drug 6 2423 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.02, 1.55]
2 Myalgias 5 3014 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.81, 1.60]
3 Increased liver chemistries 3 1427 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.72, 1.43]
4 Cough 4 2093 Risk Ratio (M-H, Random, 95% CI) 2.34 [0.77, 7.08]
5 Dyspepsia/gastrointestinal
irritation
4 3417 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.64, 2.74]
6 Bleeding 1 378 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.45, 35.46]
Analysis 1.1. Comparison 1 Mortality, cardiovascular events, and adverse events, Outcome 1 All-cause
mortality.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 1 Mortality, cardiovascular events, and adverse events
Outcome: 1 All-cause mortality
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 5/779 2/682 12.4 % 2.19 [ 0.43, 11.24 ]
UMPIRE 2013 17/1002 15/1002 87.6 % 1.13 [ 0.57, 2.26 ]
Total (95% CI) 1781 1684 100.0 % 1.26 [ 0.67, 2.38 ]
Total events: 22 (Experimental), 17 (Control)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Mortality, cardiovascular events, and adverse events, Outcome 2 Cardiovascular
events.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 1 Mortality, cardiovascular events, and adverse events
Outcome: 2 Cardiovascular events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Malekzadeh 2010 0/241 1/234 4.2 % 0.32 [ 0.01, 7.91 ]
UMPIRE 2013 50/1002 35/1002 95.8 % 1.43 [ 0.94, 2.18 ]
Total (95% CI) 1243 1236 100.0 % 1.38 [ 0.91, 2.10 ]
Total events: 50 (Experimental), 36 (Control)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Mortality, cardiovascular events, and adverse events, Outcome 3 Any adverse
event.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 1 Mortality, cardiovascular events, and adverse events
Outcome: 3 Any adverse event
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRUCIAL 2011 380/779 300/682 53.6 % 1.11 [ 0.99, 1.24 ]
CUSP 2009 21/66 22/64 3.7 % 0.93 [ 0.57, 1.51 ]
Malekzadeh 2010 97/241 71/234 12.1 % 1.33 [ 1.04, 1.70 ]
PILL 2011 81/189 59/189 9.9 % 1.37 [ 1.05, 1.80 ]
TOGETHER 2010 18/122 11/122 1.8 % 1.64 [ 0.81, 3.32 ]
UMPIRE 2013 118/1002 102/1002 17.1 % 1.16 [ 0.90, 1.49 ]
Wald 2012 24/86 11/86 1.8 % 2.18 [ 1.14, 4.17 ]
Total (95% CI) 2485 2379 100.0 % 1.19 [ 1.09, 1.30 ]
Total events: 739 (Experimental), 576 (Control)
Heterogeneity: Chi2 = 8.60, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 3.94 (P = 0.000080)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Blood pressure, Outcome 1 Systolic blood pressure.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 2 Blood pressure
Outcome: 1 Systolic blood pressure
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 12.6 % -9.80 [ -11.55, -8.05 ]
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 9.8 % -8.30 [ -13.31, -3.29 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 10.4 % -2.40 [ -6.81, 2.01 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 11.4 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 8.0 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 12.6 % -7.40 [ -9.12, -5.68 ]
TOGETHER 2010 118 -4 (11) 115 -1 (12.5) 11.7 % -3.00 [ -6.03, 0.03 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 12.7 % -1.80 [ -3.28, -0.32 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 10.8 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 2950 2837 100.0 % -7.02 [ -10.18, -3.87 ]
Heterogeneity: Tau2 = 19.82; Chi2 = 98.50, df = 8 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Blood pressure, Outcome 2 Diastolic blood pressure.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 2 Blood pressure
Outcome: 2 Diastolic blood pressure
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -10.5 (10.2) 657 -5.3 (9.5) 12.8 % -5.20 [ -6.23, -4.17 ]
CUSP 2009 63 -9.1 (8.5) 60 -5.8 (10.9) 8.9 % -3.30 [ -6.77, 0.17 ]
Malekzadeh 2010 241 -0.8 (14.8) 234 -0.1 (14.4) 10.4 % -0.70 [ -3.33, 1.93 ]
PILL 2011 189 -8.1 (10.2) 189 -2.9 (10.3) 11.3 % -5.20 [ -7.27, -3.13 ]
Soliman 2009 99 -11.3 (12.3) 104 -10.8 (12) 9.1 % -0.50 [ -3.85, 2.85 ]
TIPS 2009 392 -8.1 (8.1) 390 -2.5 (8.1) 12.7 % -5.60 [ -6.74, -4.46 ]
TOGETHER 2010 118 -1.7 (8.2) 115 -1.1 (7) 11.5 % -0.60 [ -2.56, 1.36 ]
UMPIRE 2013 1002 -4.6 (9.14) 1002 -3.1 (9.13) 13.0 % -1.50 [ -2.30, -0.70 ]
Wald 2012 86 -9.8 (8) 86 0 (10) 10.2 % -9.80 [ -12.51, -7.09 ]
Total (95% CI) 2950 2837 100.0 % -3.65 [ -5.44, -1.85 ]
Heterogeneity: Tau2 = 6.30; Chi2 = 87.01, df = 8 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.98 (P = 0.000070)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Blood pressure, Outcome 3 Systolic blood pressure: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 2 Blood pressure
Outcome: 3 Systolic blood pressure: primary prevention trials
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CUSP 2009 63 -13.4 (12.6) 60 -5.1 (15.5) 13.1 % -8.30 [ -13.31, -3.29 ]
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 13.9 % -2.40 [ -6.81, 2.01 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 15.3 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 10.6 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 16.9 % -7.40 [ -9.12, -5.68 ]
TOGETHER 2010 118 -4 (11) 115 -1 (12.5) 15.7 % -3.00 [ -6.03, 0.03 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 14.4 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 1188 1178 100.0 % -7.45 [ -11.05, -3.84 ]
Heterogeneity: Tau2 = 19.25; Chi2 = 43.81, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.05 (P = 0.000052)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Blood pressure, Outcome 4 Systolic blood pressure: 3+ drugs only.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 2 Blood pressure
Outcome: 4 Systolic blood pressure: 3+ drugs only
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Malekzadeh 2010 241 -3.7 (23.9) 234 -1.3 (25.1) 16.0 % -2.40 [ -6.81, 2.01 ]
PILL 2011 189 -16.7 (16.2) 189 -6.8 (16.5) 17.3 % -9.90 [ -13.20, -6.60 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 12.9 % -1.90 [ -8.86, 5.06 ]
TIPS 2009 392 -12.4 (12.3) 390 -5 (12.3) 18.6 % -7.40 [ -9.12, -5.68 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 18.7 % -1.80 [ -3.28, -0.32 ]
Wald 2012 86 -17.9 (10.4) 86 0 (16) 16.5 % -17.90 [ -21.93, -13.87 ]
Total (95% CI) 2009 2005 100.0 % -7.00 [ -11.40, -2.60 ]
Heterogeneity: Tau2 = 26.38; Chi2 = 74.66, df = 5 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Blood pressure, Outcome 5 Systolic blood pressure: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 2 Blood pressure
Outcome: 5 Systolic blood pressure: comparator as usual care
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -19.8 (17.1) 657 -10 (16.4) 36.7 % -9.80 [ -11.55, -8.05 ]
Soliman 2009 99 -28.8 (24.9) 104 -26.9 (25.7) 26.3 % -1.90 [ -8.86, 5.06 ]
UMPIRE 2013 1002 -7.8 (17.7) 1002 -6 (16.1) 37.0 % -1.80 [ -3.28, -0.32 ]
Total (95% CI) 1861 1763 100.0 % -4.76 [ -11.24, 1.71 ]
Heterogeneity: Tau2 = 28.89; Chi2 = 47.68, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Cholesterol, Outcome 1 Total cholesterol.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 3 Cholesterol
Outcome: 1 Total cholesterol
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 11.8 % -0.47 [ -0.52, -0.42 ]
CUSP 2009 63 -0.72 (0.32) 60 0.09 (0.37) 11.6 % -0.81 [ -0.93, -0.69 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 10.8 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 11.1 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 9.8 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 11.5 % -0.93 [ -1.09, -0.77 ]
TOGETHER 2010 118 -1.47 (0.71) 115 0.1 (0.63) 11.4 % -1.57 [ -1.74, -1.40 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 11.7 % 0.0 [ -0.09, 0.09 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 10.3 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 2933 2636 100.0 % -0.75 [ -1.05, -0.46 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 345.48, df = 8 (P<0.00001); I2 =98%
Test for overall effect: Z = 5.01 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Cholesterol, Outcome 2 LDL cholesterol.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 3 Cholesterol
Outcome: 2 LDL cholesterol
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.66 (0.71) 657 0.07 (0.81) 13.0 % -0.73 [ -0.81, -0.65 ]
CUSP 2009 63 -1.03 (0.44) 59 0.13 (0.69) 12.3 % -1.16 [ -1.37, -0.95 ]
Malekzadeh 2010 241 -0.6 (0.56) 234 -0.15 (0.96) 12.7 % -0.45 [ -0.59, -0.31 ]
PILL 2011 189 -0.93 (0.96) 189 -0.18 (0.96) 12.4 % -0.75 [ -0.94, -0.56 ]
TIPS 2009 375 -0.7 (0.79) 189 0.02 (0.8) 12.7 % -0.72 [ -0.86, -0.58 ]
TOGETHER 2010 118 -1.27 (0.6) 115 0.01 (0.65) 12.6 % -1.28 [ -1.44, -1.12 ]
UMPIRE 2013 1002 -0.15 (1.49) 1002 -0.11 (1.48) 12.8 % -0.04 [ -0.17, 0.09 ]
Wald 2012 86 -1.4 (0.95) 86 0 (0.9) 11.6 % -1.40 [ -1.68, -1.12 ]
Total (95% CI) 2834 2531 100.0 % -0.81 [ -1.09, -0.53 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 205.35, df = 7 (P<0.00001); I2 =97%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Cholesterol, Outcome 3 Total cholesterol: primary prevention trials.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 3 Cholesterol
Outcome: 3 Total cholesterol: primary prevention trials
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CUSP 2009 63 -0.72 (0.32) 59 0.09 (0.37) 15.7 % -0.81 [ -0.93, -0.69 ]
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 14.0 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 14.6 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 12.1 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 15.4 % -0.93 [ -1.09, -0.77 ]
TOGETHER 2010 118 -1.47 (0.71) 115 0.1 (0.63) 15.2 % -1.57 [ -1.74, -1.40 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 13.0 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 1171 976 100.0 % -0.92 [ -1.18, -0.65 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 71.00, df = 6 (P<0.00001); I2 =92%
Test for overall effect: Z = 6.76 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
49Fixed-dose combination therapy for the prevention of cardiovascular disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Cholesterol, Outcome 4 Total cholesterol: 3+ drugs only.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 3 Cholesterol
Outcome: 4 Total cholesterol: 3+ drugs only
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Malekzadeh 2010 241 -0.89 (1.53) 234 -0.27 (1.39) 16.6 % -0.62 [ -0.88, -0.36 ]
PILL 2011 189 -0.99 (1.24) 189 -0.15 (0.96) 16.9 % -0.84 [ -1.06, -0.62 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 15.6 % -0.40 [ -0.79, -0.01 ]
TIPS 2009 375 -0.75 (0.9) 189 0.18 (0.9) 17.3 % -0.93 [ -1.09, -0.77 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 17.5 % 0.0 [ -0.09, 0.09 ]
Wald 2012 86 -1.16 (1.18) 86 0 (1) 16.1 % -1.16 [ -1.49, -0.83 ]
Total (95% CI) 1992 1804 100.0 % -0.65 [ -1.10, -0.21 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 156.12, df = 5 (P<0.00001); I2 =97%
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Cholesterol, Outcome 5 Total cholesterol: comparator as usual care.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 3 Cholesterol
Outcome: 5 Total cholesterol: comparator as usual care
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CRUCIAL 2011 760 -0.45 (0.48) 657 0.02 (0.47) 36.9 % -0.47 [ -0.52, -0.42 ]
Soliman 2009 99 -1.4 (1.2) 104 -1 (1.6) 26.8 % -0.40 [ -0.79, -0.01 ]
UMPIRE 2013 1002 -0.1 (1.03) 1002 -0.1 (1.03) 36.3 % 0.0 [ -0.09, 0.09 ]
Total (95% CI) 1861 1763 100.0 % -0.28 [ -0.66, 0.10 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 80.16, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Adverse events, Outcome 1 Discontinuation of study drug.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 1 Discontinuation of study drug
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 7/66 6/64 4.5 % 1.13 [ 0.40, 3.18 ]
Malekzadeh 2010 24/241 15/234 11.3 % 1.55 [ 0.84, 2.89 ]
PILL 2011 44/189 33/189 24.5 % 1.33 [ 0.89, 2.00 ]
TIPS 2009 66/412 83/612 49.6 % 1.18 [ 0.88, 1.59 ]
TOGETHER 2010 15/122 11/122 8.2 % 1.36 [ 0.65, 2.85 ]
Wald 2012 0/86 2/86 1.9 % 0.20 [ 0.01, 4.11 ]
Total (95% CI) 1116 1307 100.0 % 1.26 [ 1.02, 1.55 ]
Total events: 156 (Experimental), 150 (Control)
Heterogeneity: Chi2 = 2.21, df = 5 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Adverse events, Outcome 2 Myalgias.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 2 Myalgias
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PILL 2011 13/189 14/189 26.3 % 0.93 [ 0.45, 1.92 ]
Soliman 2009 29/105 26/111 47.4 % 1.18 [ 0.75, 1.86 ]
TOGETHER 2010 6/122 7/122 13.1 % 0.86 [ 0.30, 2.48 ]
UMPIRE 2013 3/1002 6/1002 11.3 % 0.50 [ 0.13, 1.99 ]
Wald 2012 9/86 1/86 1.9 % 9.00 [ 1.17, 69.51 ]
Total (95% CI) 1504 1510 100.0 % 1.14 [ 0.81, 1.60 ]
Total events: 60 (Experimental), 54 (Control)
Heterogeneity: Chi2 = 5.90, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Adverse events, Outcome 3 Increased liver chemistries.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 3 Increased liver chemistries
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CUSP 2009 1/66 0/64 0.9 % 2.91 [ 0.12, 70.15 ]
Malekzadeh 2010 43/241 38/234 70.0 % 1.10 [ 0.74, 1.64 ]
TIPS 2009 12/412 16/410 29.1 % 0.75 [ 0.36, 1.56 ]
Total (95% CI) 719 708 100.0 % 1.01 [ 0.72, 1.43 ]
Total events: 56 (Experimental), 54 (Control)
Heterogeneity: Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Adverse events, Outcome 4 Cough.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 4 Cough
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Malekzadeh 2010 2/241 0/234 9.8 % 4.86 [ 0.23, 100.60 ]
PILL 2011 19/189 3/189 25.4 % 6.33 [ 1.91, 21.05 ]
Soliman 2009 22/412 12/612 31.7 % 2.72 [ 1.36, 5.44 ]
TIPS 2009 18/105 25/111 33.2 % 0.76 [ 0.44, 1.31 ]
Total (95% CI) 947 1146 100.0 % 2.34 [ 0.77, 7.08 ]
Total events: 61 (Experimental), 40 (Control)
Heterogeneity: Tau2 = 0.88; Chi2 = 15.48, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Adverse events, Outcome 5 Dyspepsia/gastrointestinal irritation.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 5 Dyspepsia/gastrointestinal irritation
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
PILL 2011 23/189 6/189 24.5 % 3.83 [ 1.60, 9.20 ]
Soliman 2009 20/105 15/111 30.0 % 1.41 [ 0.76, 2.60 ]
TIPS 2009 5/412 9/407 20.6 % 0.55 [ 0.19, 1.62 ]
UMPIRE 2013 10/1002 11/1002 25.0 % 0.91 [ 0.39, 2.13 ]
Total (95% CI) 1708 1709 100.0 % 1.33 [ 0.64, 2.74 ]
Total events: 58 (Experimental), 41 (Control)
Heterogeneity: Tau2 = 0.36; Chi2 = 8.97, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Adverse events, Outcome 6 Bleeding.
Review: Fixed-dose combination therapy for the prevention of cardiovascular disease
Comparison: 4 Adverse events
Outcome: 6 Bleeding
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PILL 2011 4/189 1/189 100.0 % 4.00 [ 0.45, 35.46 ]
Total (95% CI) 189 189 100.0 % 4.00 [ 0.45, 35.46 ]
Total events: 4 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Polypill content by trial
Study Polypill contents (dose) Comparator
CRUCIAL 2011 Amlodipine 5 to 10 mg
Atorvastatin 10mg1
Usual care
CUSP 2009 Amlodipine 5 mg
Atorvastatin 20 mg
Placebo
Malekzadeh 2010 Aspirin 81 mg
Atorvastatin 20 mg
Enalapril 2.5 mg
Hydrochlorothiazide 12.5 mg
Placebo
PILL 2011 Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 20 mg
Placebo
Soliman 2009 Aspirin 75 mg
Hydrochlorothiazide 12.5 mg
Lisinopril 10 mg
Simvastatin 20 mg
Usual care
TIPS 2009 Aspirin 100 mg
Atenolol 50 mg
Hydrochlorothiazide 12.5 mg
Ramipril 5 mg
Simvastatin 20 mg
8 other drug/drug combination groups:
1) Aspirin 100mg
2) Aspirin 100mg, hydrochlorothiazide 12.5mg,
atenolol 50mg, ramipril 5mg
3) Hydrochlorothiazide 12.5mg
4) Hydrochlorothiazide 12.5mg, atenolol 50mg
5) Hydrochlorothiazide 12.5mg, ramipril 5mg
6) Hydrochlorothiazide 12.5mg, atenolol 50mg,
ramipril 5mg
7) Ramipril 5mg, atenolol 50mg
8) Simvastatin 20mg
TOGETHER 2010 Amlodipine 5 to 10 mg
Atorvastatin 10mg
Amlodipine 5 to 10 mg
UMPIRE 2013 Aspirin 75mg
Atenolol 50mg
Lisinopril 40mg
Simvastatin 40mg
Usual care
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Table 1. Polypill content by trial (Continued)
or
Aspirin 75mg
Hydrochlorothiazide 12.5mg
Lisinopril 40mg
Simvastatin 40mg
Wald 2012 Amlodipine 2.5 mg
Hydrochlorothiazide 12.5 mg
Losartan 25 mg
Simvastatin 40mg
Placebo
1 Site investigators could request dosages of amlodipine and atorvastatin 5/20 mg and 10/20 mg
A P P E N D I C E S
Appendix 1. Search strategies 2012
The Cochrane Library
#1 MeSH descriptor Cardiovascular Diseases explode all trees
#2 cardio*
#3 cardia*
#4 heart*
#5 coronary*
#6 angina*
#7 ventric*
#8 myocard*
#9 pericard*
#10 isch?em*
#11 emboli*
#12 arrhythmi*
#13 thrombo*
#14 atrial fibrillat*
#15 tachycardi*
#16 endocardi*
#17 (sick next sinus)
#18 MeSH descriptor Stroke explode all trees
#19 (stroke or stokes)
#20 cerebrovasc*
#21 cerebral vascular
#22 apoplexy
#23 (brain near/2 accident)
#24 ((brain* or cerebral or lacunar) near/2 infarct*)
#25 MeSH descriptor Hypertension explode all trees
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#26 hypertensi*
#27 peripheral next arter* next disease*
#28 ((high or increased or elevated) near/2 (blood next pressure))
#29 MeSH descriptor Hyperlipidemias explode all trees
#30 hyperlipid*
#31 hyperlip?emia*
#32 hypercholesterol*
#33 hypercholester?emia*
#34 hyperlipoprotein?emia*
#35 hypertriglycerid?emia*
#36 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35)
#37 MeSH descriptor Drug Combinations, this term only
#38 polypill*
#39 (drug near/2 combin*)
#40 ((multi* or several) near/2 (ingredient* or component))
#41 policap
#42 quintapill
#43 (single near/2 pill* near/2 comb*)
#44 single-pill
#45 Red Heart pill*
#46 (#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 36 and 46, from 2000 to 2012
MEDLINE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp Stroke/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
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27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 randomised controlled trial.pt.
48 controlled clinical trial.pt.
49 randomised.ab.
50 placebo.ab.
51 drug therapy.fs.
52 randomly.ab.
53 trial.ab.
54 groups.ab.
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp animals/ not humans.sh.
57 55 not 56
58 36 and 46
59 58 and 57
60 limit 59 to yr=“2000 -Current”
EMBASE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
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17 (sick adj sinus).tw.
18 exp cerebrovascular disease/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 36 and 46
48 random$.tw.
49 factorial$.tw.
50 crossover$.tw.
51 cross over$.tw.
52 cross-over$.tw.
53 placebo$.tw.
54 (doubl$ adj blind$).tw.
55 (singl$ adj blind$).tw.
56 assign$.tw.
57 allocat$.tw.
58 volunteer$.tw.
59 crossover procedure/
60 double blind procedure/
61 randomised controlled trial/
62 single blind procedure/
63 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64 (animal/ or nonhuman/) not human/
65 63 not 64
66 47 and 65
67 limit 66 to yr=“2000 -Current”
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ISI Web of Science
25 #24 AND #23
24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
23 #22 AND #14
22 #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15
21 TS=(single-pill or “red heart pill”)
20 TS=(single near/2 pill* near/2 comb*)
19 TS=(policap or quintapill)
18 TS=(several near/2 ingredient* or several near/2 component)
17 TS=(multi* near/2 ingredient* or multi* near/2 component)
16 TS=(drug near/2 combin*)
15 TS=polypill*
14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
13 TS=(hyperlipid* or hyperlip?emia* or hyperchlosterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
12 TS=(high near/2 “blood pressure” or increased near/2 “blood pressure” or elevated near/2 “blood pressure”)
11 TS=(hypertensi* or “peripheral arter* disease*”)
10 TS=(brain* near/2 infarct* OR cerebral near/2 infarct* OR lacunar near/2 infarct*)
9 TS=(brain near/2 accident)
8 TS=apoplexy
7 TS=(stroke or strokes or cerebrovasc* or “cerebral vascular”)
6 TS=(“sick sinus”)
5 TS=(tachycardi* or endocardi*)
4 TS=“atrial fibrillat*”
3 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thromo*)
2 TS=(cardia* or heart* or coronary* or angina* or ventric* or myocard*)
1 TS=(cardio)
Appendix 2. Search strategies 2013
The Cochrane Library
#1 MeSH descriptor Cardiovascular Diseases explode all trees
#2 cardio*
#3 cardia*
#4 heart*
#5 coronary*
#6 angina*
#7 ventric*
#8 myocard*
#9 pericard*
#10 isch?em*
#11 emboli*
#12 arrhythmi*
#13 thrombo*
#14 atrial fibrillat*
#15 tachycardi*
#16 endocardi*
#17 (sick next sinus)
#18 MeSH descriptor Stroke explode all trees
#19 (stroke or stokes)
62Fixed-dose combination therapy for the prevention of cardiovascular disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#20 cerebrovasc*
#21 cerebral vascular
#22 apoplexy
#23 (brain near/2 accident)
#24 ((brain* or cerebral or lacunar) near/2 infarct*)
#25 MeSH descriptor Hypertension explode all trees
#26 hypertensi*
#27 peripheral next arter* next disease*
#28 ((high or increased or elevated) near/2 (blood next pressure))
#29 MeSH descriptor Hyperlipidemias explode all trees
#30 hyperlipid*
#31 hyperlip?emia*
#32 hypercholesterol*
#33 hypercholester?emia*
#34 hyperlipoprotein?emia*
#35 hypertriglycerid?emia*
#36 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35)
#37 MeSH descriptor Drug Combinations, this term only
#38 polypill*
#39 (drug near/2 combin*)
#40 ((multi* or several) near/2 (ingredient* or component))
#41 policap
#42 quintapill
#43 (single near/2 pill* near/2 comb*)
#44 single-pill
#45 Red Heart pill*
#46 (#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45)
#47 36 and 46, from 2000 to 2013
MEDLINE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp Stroke/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
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21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 randomized controlled trial.pt.
48 controlled clinical trial.pt.
49 randomized.ab.
50 placebo.ab.
51 drug therapy.fs.
52 randomly.ab.
53 trial.ab.
54 groups.ab.
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp animals/ not humans.sh.
57 55 not 56
58 36 and 46
59 58 and 57
60 limit 59 to yr=“2000 -Current”
61 (2012* or 2013*).ed.
62 60 and 61
63 limit 62 to “core clinical journals (aim)”
EMBASE Ovid
1 exp Cardiovascular Diseases/
2 cardio*.tw.
3 cardia*.tw.
4 heart*.tw.
5 coronary*.tw.
6 angina*.tw.
7 ventric*.tw.
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8 myocard*.tw.
9 pericard*.tw.
10 isch?em*.tw.
11 emboli*.tw.
12 arrhythmi*.tw.
13 thrombo*.tw.
14 atrial fibrillat*.tw.
15 tachycardi*.tw.
16 endocardi*.tw.
17 (sick adj sinus).tw.
18 exp cerebrovascular disease/
19 (stroke or stokes).tw.
20 cerebrovasc*.tw.
21 cerebral vascular.tw.
22 apoplexy.tw.
23 (brain adj2 accident*).tw.
24 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25 exp Hypertension/
26 hypertensi*.tw.
27 peripheral arter* disease*.tw.
28 ((high or increased or elevated) adj2 blood pressure).tw.
29 exp Hyperlipidemias/
30 hyperlipid*.tw.
31 hyperlip?emia*.tw.
32 hypercholesterol*.tw.
33 hypercholester?emia*.tw.
34 hyperlipoprotein?emia*.tw.
35 hypertriglycerid?emia*.tw.
36 or/1-35
37 Drug Combinations/
38 polypill*.tw.
39 (drug adj2 combin*).tw.
40 ((multi* or several) adj2 (ingredient* or component*)).tw.
41 policap.tw.
42 quintapill.tw.
43 (single adj2 pill* adj2 comb*).tw.
44 single-pill.tw.
45 Red Heart pill*.tw.
46 or/37-45
47 36 and 46
48 random$.tw.
49 factorial$.tw.
50 crossover$.tw.
51 cross over$.tw.
52 cross-over$.tw.
53 placebo$.tw.
54 (doubl$ adj blind$).tw.
55 (singl$ adj blind$).tw.
56 assign$.tw.
57 allocat$.tw.
58 volunteer$.tw.
59 crossover procedure/
60 double blind procedure/
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61 randomized controlled trial/
62 single blind procedure/
63 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62
64 (animal/ or nonhuman/) not human/
65 63 not 64
66 47 and 65
67 limit 66 to yr=“2000 -Current”
68 (2012* or 2013*).em.
69 67 and 68
70 limit 69 to priority journals
ISI Web of Science
25 #24 AND #23
24 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
23 #22 AND #14
22 #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15
21 TS=(single-pill or “red heart pill”)
20 TS=(single near/2 pill* near/2 comb*)
19 TS=(policap or quintapill)
18 TS=(several near/2 ingredient* or several near/2 component)
17 TS=(multi* near/2 ingredient* or multi* near/2 component)
16 TS=(drug near/2 combin*)
15 TS=polypill*
14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
13 TS=(hyperlipid* or hyperlip?emia* or hyperchlosterol* or hypercholester?emia* or hyperlipoprotein?emia* or hypertriglycerid?
emia*)
12 TS=(high near/2 “blood pressure” or increased near/2 “blood pressure” or elevated near/2 “blood pressure”)
11 TS=(hypertensi* or “peripheral arter* disease*”)
10 TS=(brain* near/2 infarct* OR cerebral near/2 infarct* OR lacunar near/2 infarct*)
9 TS=(brain near/2 accident)
8 TS=apoplexy
7 TS=(stroke or strokes or cerebrovasc* or “cerebral vascular”)
6 TS=(“sick sinus”)
5 TS=(tachycardi* or endocardi*)
4 TS=“atrial fibrillat*”
3 TS=(pericard* or isch?em* or emboli* or arrhythmi* or thromo*)
2 TS=(cardia* or heart* or coronary* or angina* or ventric* or myocard*)
1 TS=(cardio)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The background section has been shortened. Previous inclusion of HDL cholesterol and triglycerides as outcomes were excluded, and
subgroup analysis evaluating the comparator group as usual care versus placebo or inactive control added.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticholesteremic Agents [∗administration & dosage]; Antihypertensive Agents [∗administration & dosage]; Aspirin [∗administration
& dosage]; Cardiovascular Diseases [mortality; ∗prevention & control]; Drug Combinations; Placebo Effect; Platelet Aggregation
Inhibitors [∗administration & dosage]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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